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Abstract
Purpose of the Review Comorbidity of alcohol and tobacco
use is highly prevalent and may exacerbate the health effects
of either substance alone. However, the mechanisms underly-
ing this comorbidity are not well understood. This review will
examine the evidence for shared neurobiological mechanisms
of alcohol and nicotine comorbidity and experimental studies
of the behavioural consequences of these interactions.
Recent Findings Studies examining the shared neurobiology of
alcohol and nicotine have identified twomainmechanisms of co-
morbidity: (1) cross-reinforcement via the mesolimbic dopamine
pathway and (2) cross-tolerance via shared genetic and nAChR
interaction. Animal and human psychopharmacological studies
demonstrate support for these twomechanisms of comorbidity.
Summary Human behavioural studies indicate that (1) alcohol
and tobacco potentiate each other’s rewarding effects and (2)
nicotinereduces thesedativeand intoxicationeffectsofalcohol.
Together, these findings provide a strong evidence base to sup-
port the role of the cross-reinforcement and cross-tolerance as
mechanismsunderlyingthecomorbidityofalcoholand tobacco
use. Methodological concerns in the literature and recommen-
dations for future studies are discussed alongside implications
for treatment of comorbid alcohol and tobacco use.
Keywords Alcohol . Nicotine . Comorbidity .
Psychopharmacology . Cross-reinforcement . Cross-tolerance
Introduction
Alcohol and tobacco use independently represent major public
health problems, associated with preventable disease and death.
Comorbid use of alcohol and tobacco may exacerbate the health
effectsofeither substancealone,withcomorbidityassociatedwith
increasedriskforsometypesofcancer,e.g.mouthandthroat[1–3]
and liver cancer [4, 5]. Additionally, for alcohol-dependent indi-
viduals, comorbid use increases the risk of tobacco-related dis-
eases (e.g. heart disease and lung disease) [6] and death from
tobacco-related complications [7].
Alcohol and tobacco use are highly comorbid [8] and there is a
strong correlation between alcohol and nicotine dependency.
Alcohol-dependent individuals are three times more likely to
smoke than the general population, and individuals who are de-
pendenton tobaccoare four timesmore likely tobealcoholdepen-
dent [9]. Furthermore, alcohol-dependent smokers havemore se-
vere nicotine dependency and experience greater difficulty quit-
ting than non-alcohol-dependent smokers [10]. Consequently,
treatment for drug dependency has faced the challenge of tackling
comorbid addiction, with uncertainty regarding whether to treat
both substance problems together or separately. Typically, the pri-
mary addiction is treated first. However, tobacco dependency is
rarely treated in alcohol-dependent individuals as treatment pro-
viders view quitting both substances at the same time too difficult
and suggest that tobacco treatment may negatively impact inter-
ventions for alcohol dependency.
Psychopharmacology of Comorbidity
Whilst comorbidity of alcohol and tobacco use is clearly evi-
dent, the mechanisms underlying this association and conse-
quences for t rea tment are not wel l unders tood.
Psychopharmacological studies represent an opportunity for
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improving our understanding of alcohol and tobacco comor-
bidity by examining the shared neurobiological mechanisms
and the subsequent behavioural effects of these drugs.
Examining the interaction between concomitant alcohol and
nicotine use and dependency is a major challenge for re-
searchers as these substances have many shared neural mech-
anisms, making it difficult to tease the behavioural effects of
each drug apart. Additionally, the comorbid effects of alcohol
and nicotine are difficult to study given the influence of indi-
vidual differences in age and gender and differential physio-
logical and behavioural effects dependent on the amount of
the drug consumed [11, 12]. In this review, we will examine
the evidence for shared neurobiological mechanisms of alco-
hol and nicotine comorbidity and experimental studies of the
behavioural consequences of these interactions. Examination
of these specific shared mechanisms will contribute to our
understanding of the high comorbidity between alcohol and
nicotine use and dependency and have important implications
for comorbid treatment.
NeurobiologicalMechanisms of Alcohol and Tobacco
Use and Dependency
Initiation and experimentation with alcohol and nicotine is
largely due to the acute pharmacological effects of these
drugs. Nicotine is a stimulant, which can increase alertness
and improve concentration, whereas alcohol is a depressant
drug with acute effects ranging from increased mood and re-
laxation to decreased inhibitory control, loss of motor control
and reduced reaction times. Acutely, nicotine and alcohol also
show interactional effects; e.g. nicotine reduces the sedative
effects of alcohol [13] and alcohol potentiates the rewarding
effects of nicotine [14]. However, the neurobiological mech-
anisms of the acute effects for nicotine and alcohol differ.
Nicotine primarily acts on the brain via binding and activation
of the nicotinic acetylcholine receptor (nAChR). However,
alcohol does not bind to one receptor in particular, with acti-
vation of many different receptors of several neurotransmit-
ters, e.g. serotonin, dopamine and gamma-aminobutyric acid.
Despite these differences in mechanisms of acute effects, there
is a growing body of evidence for shared neurobiological
mechanisms that underlie the comorbid use of and dependen-
cy on alcohol and nicotine.
Studies examining the shared neurobiology and subsequent
behavioural effects of alcohol and nicotine have identified two
mainmechanisms: (1) cross-reinforcement via the mesolimbic
dopamine pathway and (2) cross-tolerance via shared genetic
and nAChR interaction. Shared psychosocial factors have also
been highlighted as a mechanism underlying comorbid use;
however these will not be discussed here given the focus of
the review on psychopharmacological mechanisms of comor-
bidity. The following sections will discuss the neural
pathways and supporting behavioural evidence for these two
mechanisms, evaluating their contribution to our understand-
ing of alcohol and nicotine comorbidity.
Cross-Reinforcement
Cross-reinforcement refers to the ability of alcohol and nico-
tine to enhance the motivation to consume the other drug by
acting on shared neurobiological mechanisms that underlie the
reinforcement of drug effects. Interaction between the rein-
forcing effects of alcohol and nicotine may occur during acute
comorbid use (e.g. intoxication) or maymanifest in changes in
neurobiological function following repeated use of one or
both drugs [15]. Alcohol and nicotine share a reward activa-
tion pathway, where both drugs potentiate the rewarding ef-
fects of each other via activation of the mesolimbic dopamine
pathway. The mesolimbic neural pathway originates in dopa-
minergic neurons in the ventral tegmental area (VTA) that
project and terminate in the nucleus accumbens (NAcc) in
the ventral striatum. The experience of reward and reward-
seeking is accompanied by release of dopamine in the
mesolimbic pathway for natural rewards, e.g. food and sex
and drug rewards [16–19]. Specifically, alcohol and nicotine
increase dopaminergic neuron firing [20–22] and dopamine
release in the mesolimbic pathway [23–25]. Nicotine may
activate the mesolimbic pathway via nicotinic acetylcholine
receptors (nAChRs) that stimulate VTA neurons to release
dopamine in regions including the NAcc [26–30]. The contri-
bution of nAChRs in the reinforcing effects of nicotine is
supported by evidence of reduced nicotine administration fol-
lowing blockade of nicotinic receptors in the VTA [31].
Alcohol may influence the mesolimbic pathway by a number
of mechanisms. Firstly, alcohol’s interaction with nAChRs
may underlie the reinforcing properties of alcohol [32, 33]
where nicotine receptor antagonists are shown to increase vol-
untary alcohol consumption [34]. Secondly, self-
administration of alcohol leads to extracellular dopamine re-
lease in the NAcc, consistent with a role for mesolimbic do-
pamine in alcohol reinforcement [35–37]. In addition, alcohol
has been shown to change synaptic plasticity in the
mesolimbic pathway via dopaminergic mechanisms that may
also underlie the development of alcohol reinforcement [38].
Supporting studies have shown that injections of dopamine-
releasing agents in the NAcc increases alcohol consumption,
whilst injection of agents that reduce dopamine release into
the VTA decreases alcohol intake [39].
Research has also examined the role of the mesolimbic
pathway to understand the cross-reinforcement between nico-
tine and alcohol. Evidence for the role of mesolimbic dopa-
mine in interface between alcohol and nicotine has shown the
pharmacological blockade of nAChRs in the VTA reduces
alcohol intake, indicating that the rewarding effects of alcohol
Curr Addict Rep
may be dependent on nicotinic receptors [40]. Additionally,
microdialysis studies have lent support to the notion that al-
cohol and nicotine act synergistically on behaviour via dopa-
mine release in the NAcc [41]. Tizabi and colleagues [24, 25]
have provided evidence to indicate that co-administration of
alcohol and nicotine produces an additive release of
mesolimbic dopamine in the NAcc via injections of both
drugs into the VTA. Together, these studies suggest that
mesolimbic dopamine activity is an important mechanism
contributing to the cross-reinforcement and subsequent co-
morbid use of nicotine and alcohol.
Animal Studies of Cross-Reinforcement
Animal and human studies have provided robust evidence for the
behavioural cross-reinforcement of alcohol and nicotine in sup-
port of a shared mesolimbic dopaminergic reward pathway.
Studies testingananimalmodel of cross-reinforcement havecon-
sistently demonstrated an interaction between the reinforcing ef-
fectsofnicotineandalcohol.One lineof researchhasassessed the
effects of nicotine on alcohol administration using surgically im-
planted nicotine releasing capsules or daily injections of nicotine
to chronically deliver nicotine. These studies have shown that
nicotine increases alcohol self-administration [33, 42–44] and
motivation to work for/obtain alcohol [45, 46]. Another line of
work has used a relapse/reinstatement animal model to test nico-
tine’s reinforcement effect on alcohol. Lệ and colleagues [47]
trained rats to self-administer alcohol via a lever press. Once this
behaviourwas established, itwas extinguished via the lever press
no longer delivering alcohol. Using nicotine injections, Lệ and
colleagues [47] were able to reinstate lever pressing in a dose-
dependent fashion, indicatingthatnicotineinfluencesneuralpath-
waysunderlyingalcohol seeking.Fewanimal studieshave inves-
tigated the reinforcing effects of alcohol on nicotine.
Human Studies of Cross-Reinforcement
Human studies are consistent in their support for cross-
reinforcement of nicotine and alcohol. However, in contrast
to animal studies, the majority of human research has focused
on evidence for alcohol increasing the reinforcing properties
of nicotine. A small body of research has examined alcohol’s
capability to increase urge to smoke and cigarette craving as a
measure of cross-reinforcement. One study [48] demonstrated
that alcohol (0.4, 0.8 g/kg) increased the urge to smoke in
nicotine deprived, heavy drinking, light smokers in a dose-
dependent fashion. Smoking urge increases were evident dur-
ing ascending and descending blood alcohol concentration
(BAC) and were greater for positive reinforcing effects than
negative reinforcing effects. Similarly, Glautier and colleagues
[49] examined the subjective reinforcing effects of alcohol on
nicotine, and also included a behavioural measure of cigarette
use. This addition is important as subjective cigarette craving
(as assessed in King and Epstein [48]) does not necessarily
confer to actual smoking choice. By measuring the effects of
alcohol (0.5 g/kg) on subjective effects of nicotine and
smoking typography Glauteir and colleagues [49] indicated
that alcohol increased satisfaction from smoking, length of
time spent smoking and number of puffs taken from a ciga-
rette. Together, these studies support a pharmacological prim-
ing mechanism of cross-reinforcement, where alcohol in-
creases the subjective reinforcing effects of nicotine.
Further research has examined the behavioural effects of alco-
hol’scapability to increase the rewardingeffectsofnicotineand to
increase nicotine intake. Early studies of alcohol’s reinforcing
effects on nicotine intake demonstrate that alcohol increases the
amount, rate and puff volume of cigarette smoking [50, 51].
Similarly, early studies byMello and colleagues [52, 53] indicate
that chronic alcohol administration (15–21 days) increases ciga-
rette use in moderate-heavy smokers However, these studies are
significantly limited by small sample sizes and in the case of the
majority of studies [50–52] entirely male populations. A more
recent studyhas consolidated these findingsusinga larger sample
size of social drinkers and smokers.Mitchell and colleagues [54]
examined the dose-dependent effects of alcohol (0.2, 0.4,
0.8 g/kg) vs. placeboon amount of cigarettes smoked and tempo-
ral smoking pattern. Findings indicated that in the hour following
amoderate (0.4 g/kg) or higher (0.8 g/kg) dose of alcohol, partic-
ipantssmokedmorecigarettes.However, thiseffectdidnotextend
beyond 1 h suggesting that the cross-reinforcement of alcohol on
nicotinemaybe short lived and restricted to the ascending limbof
the blood alcohol curve. This result is in contrast to evidence of
alcohol’s potentiation of the urge to smoke on the ascending and
descending limb of BAC [48].
Another body of human research has studied the ability of
nicotine to increase the reinforcingvalueof alcohol.Of these stud-
ies, several haveused a nicotinevs. placebodesign tomeasure the
effects of nicotine administration on the rewarding effects of alco-
hol. Barrett and colleagues [55] used a nicotine (1.2 mg) vs. pla-
cebo design to examine performance on a high demand, progres-
sive ratio task that rewarded participants with the opportunity to
self-administer alcohol. Findings showed that nicotine led to in-
creasedmotivation towork for alcohol and increasedalcohol con-
sumption. Acheson and colleagues [56•] examined nicotine’s (7,
14 mg) reinforcing effects on subjective ratings of alcohol and
alcohol consumption. Nicotine (14 mg) increased alcohol con-
sumption for males, but decreased alcohol consumption for fe-
males. Males also reported increased arousal following nicotine
pre-treatment, whereas females reported a decrease in positive
affect. These findings highlight the importance of studying the
effects of comorbidity inmale and female drugusers as the effects
of concurrent use of alcohol and tobaccomay differentiate by sex
or factors associatedwith sex (e.g. bodymass index) (Table 1).
Recent work has sought to extend the work of studies that
examine the effects of either alcohol or nicotine on the other
drug, by examining concurrent administration of alcohol and
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nicotine. Rose and colleagues [14] examined the effects of
alcohol (0.5 g/kg) vs. placebo and an ad lib smoking period
on subjective drug effects including stimulation and satisfac-
tion and relief of craving. Results indicated that alcohol po-
tentiated the positive rewarding effects of nicotine as indexed
by increased self-report smoking satisfaction, enhanced stim-
ulant and calming effects of nicotine and increased relief of
cigarette craving. In addition, nicotine reversed the sedative
effects of alcohol (this finding will be discussed further in the
cross-tolerance section). A further study by Kouri and col-
leagues [57] examined the effects of nicotine via transdermal
patch on the subjective and physiological effects of either a
moderate (0.4 g/kg) or high (0.7 g/kg) dose of alcohol. Results
indicated that nicotine pre-treatment increased feeling drunk,
the effects of alcohol and wanting to drink more. Furthermore,
alcohol-induced increased heart rate was enhanced following
nicotine pre-treatment. Consistent with the findings of
Mitchell and colleagues [54], these effects were most pro-
nounced in the first hour following alcohol consumption and
diminished after 2 h. A further study [58•] examined the sep-
arate and combined administration of nicotine and alcohol on
craving for each drug using a double-bind study of alcohol
(0.30 g/kg males, 0.27 g/kg females) vs. placebo and nicotine
(0.6 mg) vs. placebo. Findings indicated that combined ad-
ministration of nicotine and alcohol increased cigarette crav-
ing for all participants and alcohol craving for females and
light drinkers only. A similar study by Perkins and colleagues
[59] examined the effects of concurrently administered nico-
tine (20 μg/kg) and alcohol (0.5 g/kg) on subjective drug
effects, mood and cardiovascular response. Results showed
that combined administration of alcohol and nicotine in-
creased head-rush, intoxication, arousal cardiovascular mea-
sures. These findings suggest had an additive effect of both
drugs on pharmacological measure of drug reinforcement.
Together, this study with other discussed here demonstrates
a role for behavioural cross-reinforcement in the comorbid use
of alcohol and tobacco. The findings of these studies also lend
support for the role of the mesolimbic dopaminergic pathways
in the comorbidity of nicotine and alcohol use.
Cross-Tolerance
Tolerance is a process demonstrated following repeated drug
use, where by continued use of a fixed amount of a substance
produces a lesser effect (e.g. euphoria, buzz). Therefore, a
greater amount of the drug is required to achieve the same,
initial effect. The development of tolerance is thought to be
instrumental in the escalation of drug-intake and progression
to drug dependence. Repeated use of both alcohol and nico-
tine use can facilitate tolerance to the drugs’ pharmacological
effects [60, 61]. In addition to tolerance to each individual
substance, pharmacological interactions between alcohol andTa
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nicotine are evident in the reduction of response to one drug
via use of the other. Development of cross-tolerance may con-
tribute to the comorbid use of nicotine and alcohol use via a
mechanism of genetic predisposition [62]. Evidence has dem-
onstrated that individuals with a family history of alcohol
dependency may inherit a diminished sensitivity to the phar-
macological effects of alcohol, including less intoxication and
body sway [63]. Similarly, Health and Colleagues [64] report-
ed evidence of a role for genetic predisposition in sensitivity to
alcohol’s effects in individuals with no history of familiar
alcohol dependency. Together, these studies suggest that de-
creased reactivity to alcohol may lead to increased and heavy
alcohol use due to reduced experience of the pharmacological
effects of alcohol. Further research, has also indicated that
current smokers report a diminished intoxicating effect of al-
cohol, compared to former and non-smokers [64] and for fe-
male smokers a genetic association between smoking status
and alcohol intoxication [65]. At present, there is limited
knowledge of the precise genes involved in the effects of
nicotine on diminished response to alcohol intoxication.
However, these studies do indicate cross-tolerant effects be-
tween nicotine and alcohol that reflects a reduced response to
alcohol in those who smoke.
Another line of research has focused on nicotinic receptors
as a possible mechanism underlying the cross-tolerance of
nicotine and alcohol. Evidence has demonstrated that alcohol
enhances and inhibits the function of several nAChR subtypes
[66–68]. Through mechanisms of both enhancement and in-
hibition of nAChR subtypes, alcohol is able to affect trans-
mission at these receptors and nicotine-induced signalling
[69]. Several studies have demonstrated that modulation of
t he s e r e cep to r s can a l t e r t h e behav iou r a l and
neurotoxicological effects of alcohol [33, 69, 70], indicating
that shared nAChR sites may contribute the comorbid use of
alcohol and tobacco. A recent study indicated the role of
nAChRs in the cross-tolerant effects of both drugs. Taslim
and colleagues [71] showed that nicotine reduced alcohol-
induced incoordination via nAChR subtype function, suggest-
ing a role for nAChR subtypes α4β2 and α7 in the behaviour-
al cross-tolerance of nicotine and alcohol.
Animal Studies of Cross-Tolerance
Cross-tolerance of alcohol and nicotine is a complex process
to disentangle and evaluate given the repeated comorbid use
of both drugs in humans. However, animal studies of cross-
tolerance have demonstrated that reduction of response to
nicotine/alcohol via repeated exposure to the other drug is an
important motivating factor in comorbid use. These studies
have examined cross-tolerance between nicotine and alcohol
on numerous measures of the pharmacological effects of both
drugs, including changes in temperature and motor activity.
One body of research has assessed the effects of repeated
alcohol exposure on cross-tolerance to the effects of nicotine
in rodents. One study [72] demonstrated that chronic alcohol
administration (via a liquid diet) initiated tolerance for alco-
hol’s behavioural effects. Additionally, chronic alcohol expo-
sure induced cross-tolerance for nicotine. A further supporting
study [73] of 4-day alcohol administration in adolescent mice
demonstrated tolerance to alcohol’s hypothermic response
(i.e. reduced temperature). At 30 days post alcohol adminis-
tration, female mice were cross-tolerant to nicotine’s effects
on temperature and locomotor activity (i.e. location explora-
tion). These studies support the notion that alcohol and nico-
tine share neurobiological sites of action.
Another group of animal studies have examined the effects
of repeated nicotine administration on cross-tolerance of alco-
hol’s effects. A series of studies by Parnell, Chen and
Colleagues [74–76] have demonstrated that administration
of a range of nicotine doses (0.25, 0.5, 1, 2, 4, 6 mg/kg),
reduces peak BAC following a dose of alcohol, indicative of
cross-tolerant effect of nicotine on alcohol. Further evidence
of nicotine’s cross-tolerant effects has been provided by stud-
ies of repeated nicotine infusion in selectively bred mice.
Research has shown that inbred DBA/2 mice exposed to in-
travenous infusion of nicotine (0.25–0.8 mg/kg/h) for 10–
14 days developed tolerance for several effects of nicotine
and cross-tolerance to the hypothermic effects of alcohol
[77, 78]. These data support the genetic basis of the cross-
tolerance of nicotine and tobacco, reflecting a reduced re-
sponse to alcohol following repeated nicotine exposure.
Human Studies of Cross-Tolerance
Compared with human studies of cross-reinforcement, fewer
studies have produced translational evidence of cross-tolerant
effects of nicotine and alcohol in humans. However, of the
studies that did examine this research question, most have
examined cross-tolerance as a mechanism mitigating the aver-
sive effects of one drug on the other via measures of intoxica-
tion, craving and drug use. Several studies have investigated
the combined effects of alcohol and nicotine administration on
the subjective and behavioural interaction of these drugs. A
study by Oliver and colleagues [58•] demonstrated that co-
administration of a low-dose alcohol (0.30 g/kg males,
0.27 g/kg females) blocked the satiating effect of nicotine on
cravings to smoke. Similarly, Rose and colleagues [14] exam-
ined the effects of alcohol (0.5 g/kg) and an ad lib smoking
period on subjective drug effects. Results demonstrated that
nicotine reduced the sedative effects of alcohol. A third study
by Perkins and colleagues [59] examined the combined effects
of alcohol (0.5 g/kg) and nicotine (20 μg/kg) administration
on subjective drug effects. Findings indicated that nicotine
reduced the intoxicating effects of alcohol and eliminated al-
cohol’s sedative effects during descending BAC. Together, the
findings of these studies suggest a mechanism of alcohol and
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nicotine cross-tolerance whereby nicotine reduces the subjec-
tive intoxication and sedative effects of alcohol.
Conclusions
Studies examining the behavioural effects of alcohol contrib-
ute to our understanding of concurrent alcohol and tobacco
use in several important ways. Findings of behavioural studies
discussed here indicate the role of two key psychopharmaco-
logical mechanisms in the comorbid use of alcohol and tobac-
co; cross-reinforcement and cross-tolerance. Studies of cross-
reinforcement indicate that alcohol and nicotine potentiate
each other’s rewarding effects, as evidenced by increased
craving, subjective rewarding effects, consumption and moti-
vation to work for the other drug. Findings of these studies
indicate that the comorbidity of alcohol and tobacco use is in
part driven by an interaction between the reinforcing effects of
alcohol and nicotine on enhanced motivation to consume the
other drug. The studies reviewed here also indicate that alco-
hol and nicotine have a cross-tolerant effect, where evidence
demonstrates that nicotine reduces or blocks the sedative and
intoxication effects of alcohol. Nicotine’s attenuation of these
effects may serve to eliminate some the negative effects of
alcohol that limit alcohol consumption, e.g. tiredness and
drunkenness. Therefore, these findings suggest that the
cross-tolerance effect of nicotine on alcohol’s sedative effects
is a potential mechanism underlying comorbid use of alcohol
and nicotine.
The findings discussed here have clinical implications for
treatment of comorbid alcohol and tobacco use. Until recent-
ly, smoking and drinking were viewed as separate targets in
interventions aimed at reducing tobacco and alcohol use.
Similarly, alcohol and tobacco dependence were approached
separately or individually in treatment, with alcohol depen-
dency often being treated first, in isolation. Drobes [79]
suggests that smoking cessation programmes were deemed
as contradictory to treatment of alcohol dependency, where
tobacco dependency was regarded as a more trivial problem
compared with alcohol misuse. Furthermore, treatment of
tobacco dependency was considered to have a negative im-
pact on treatment outcomes for treatment of alcohol depen-
dency [80]. However, the research examined in this review
indicates that combined treatment of comorbid alcohol and
tobacco use may lead to more favourable treatment out-
comes. Evidence from behavioural studies of cross-
reinforcement and cross-tolerance of alcohol and tobacco is
potentially useful in identifying individuals at risk for devel-
oping heavy comorbid use of alcohol and tobacco and co-
morbid dependency. Furthermore, understanding the mecha-
nisms underlying alcohol and tobacco’s comorbid use will
improve interventions for reducing concurrent alcohol and
tobacco use. Studies of cross-tolerance [14, 58•, 59] suggest
that nicotine’s reduction of alcohol’s intoxicating and seda-
tive effects may increase the likelihood of greater alcohol
use in smokers. This finding has implications for smokers
who are looking to cut down or reduce their drinking, where
tobacco use may play a role in maintaining drinking behav-
iours. Smokers and/or health professionals treating them
should be aware of the effects nicotine has on the intoxicat-
ing effects of alcohol and of the potential of smoking to
undermine attempts to reduce drinking due to cross-
tolerance effects of alcohol and tobacco. Evidence of alco-
hol’s cross-reinforcing effect on nicotine also aids our un-
derstanding of the role of alcohol effects on nicotine reward
in smoking relapse. Research indicates that rates of success-
ful smoking cessation are reduced in smokers with current or
past alcohol problems [81], suggesting that co-current tobac-
co and alcohol use hampers smoking cessation. This finding
is supported by evidence from behavioural studies of cross-
reinforcement, indicating alcohol’s potentiating effect of nic-
otine’s rewarding effects, including alcohol’s ability to in-
crease smoking satisfaction [48] and cigarette use [54].
Together, these findings suggest that smokers who are trying
to quit should reduce their alcohol consumption or avoid
drinking. Evidence from studies of cross-reinforcement also
suggest that craving for cigarettes is increased following
alcohol consumption [48] and that smokers should also be
aware of increased cigarette cravings when drinking alcohol
during smoking cessation. Indeed, strategies for reducing
alcohol consumption may help attenuate cigarette craving
and smoking during smoking cessation.
Interpretation of the discussed findings from behav-
ioural studies, however, should be considered in light of
the following methodological limitations. Many of the
discussed studies are limited by small sample sizes, with
the smallest study having an n = 5 [50] and the largest
study having a n = 78 [58]. It is therefore important that
further research using adequately powered studies is con-
ducted to confirm the results of studies with smaller sam-
ple sizes. Many of the discussed behavioural studies were
also conducted with only male participants [50–52, 55,
57]. Studies of alcohol and nicotine administration in
male and female participants have suggested sex differ-
ences in the cross-reinforcement and cross-tolerance of
alcohol and nicotine. For example, Acheson and col-
leagues [56•] found that nicotine increased alcohol con-
sumption in males, but decreased alcohol consumption in
females. Sex differences were also reported in the subjec-
tive effects of nicotine on alcohol use. Several explana-
tions for these differences in males and females have been
suggested, including body composition and social factors
[56•]. However, the underlying reasons for sex differences
in the pharmacological effects of alcohol and tobacco
have not yet been fully explored and therefore warrant
fu r the r inves t iga t ion . Anothe r methodo log ica l
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consideration of behavioural studies is the discrimination
of alcohol’s effects during ascending and descending
BAC. Several studies point towards differential effects
of alcohol on nicotine’s rewarding effects at different
levels of BAC [48, 54, 58•]. Perkins and colleagues [13]
also outline several further methodological problems in
interpreting the studies discussed here, including difficul-
ty in controlling nicotine dosing if tobacco/cigarette
smoking is the method of administration for nicotine.
Studies have begun to use methods of nicotine delivery
other than ad lib cigarette smoking, or self-administration
of tobacco to eliminate this problem, such as transdermal
nicotine patch [57] and nicotine nasal spray [59].
However, further research is required to determine the
influence of different methods of nicotine administration.
Studies are also limited in their consideration of past his-
tory of drug use of study participants [13]. Future behav-
ioural studies of cross-reinforcement and cross-tolerance
should seek to examine the effects of nicotine and alcohol
co-administration in different categories of smokers and
drinkers (e.g. occasional, light, heavy and dependent
users). Exploration of different levels of comorbid use
will improve understanding of the role of cross-
enforcement and cross-tolerance in the initiation and
maintenance of dual drug use and the development of
comorbid abuse and dependency.
In summary, alcohol and tobacco use are highly comor-
bid behaviours, where concurrent use may potentiate the
negative effects of either substance alone. This review
identified neurobiological and behavioural evidence for
two central mechanisms underlying the comorbid use of
alcohol and tobacco; cross-reinforcement and cross-toler-
ance. The findings discussed here aid our understanding of
the mechanisms underlying alcohol and tobacco comorbid-
ity and have several important implications for the comor-
bid treatment of alcohol and tobacco use and dependency.
Development of treatment programmes should be based on
the mechanisms identified in this review to improve inter-
ventions aimed at comorbidity.
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